We evaluated the efficacy ofa new phannacokinetically enhancedformulation ojamoxiciliin/clavulanate (2,0001125 mg) twice daily fo r the treatm ent of acute bacterial rhinosinusitis (ABRS) caused by Strept oc occus pneumoniae, particula rly penicillin-resistant S pneumoniae (PRSP; penicillin minimum inhibitory concentra tions [M1Cs) :~2 f.1g111l1. A total of2,482 patients received study medicat ion (safe ty population). Ofthese, 2,324 were clini cally evaluable (effi cacy population),and 1,156 ofthem had at least one pathogen isolated at screening (bacteriology populati on). S pneumoniae was isolatedfr om TZl patients in the bacteriology population, incl uding 37 with PRS? Follow-up in the bacte riology population on days 17 through 28 revealed that atnoxi cillin/ clavulanate therapy was successfu l in 345 of371 patients with S pneumoniae inf ection (93.0 %) and in 36 of 37 patients with PRSP infection (97.3%), including 7 of8 patients (87.5%) whose amoxicillin/clavulanic acid M1Cs were 412 ug/ml or higher: Pharm acokin etically enhanced amox icillin/clavulanate was generally well tolerated, as only 2.2 % ofpati ents withdrew becaus e of adverse events. Th is agent represents a valuable new therap euti c option for the empiric treatment ofABRS, pa rticularly in areas where antimicrobial-resistant path ogens (inch /d-ing~-l a ct am a s e-p o si ti v e organisms) are prevalent, and fo r the treatm ent ofpat ients who are at increased risk of infection with PRS?
Introduction
Approx imate ly 20 mill ion ca ses of ac ute bact eri al rhino sinu sit is (A BRS) occur annua lly in th e United St ate s.I Rhinosinusiti s is th e fifth most co m mo n indication for presc rib ed antibiotic the rapy in th e Un ited States.' In rhinosinusiti s cas es known to be caused by bacteri al path ogen s, Strepto coccus pn eum oniae is the mo st common isolate.I World wide, the prevalence of res ist anc e to peni cillin by S pneumoniae is increasing. In 200 I, the prevalence of pen icillin-resistant S pn eumoni ae (PRS P; penicillin minimum inh ibitory concentrations [MICs]:~2 ug/rnl ) in the Alexand er Proj ect surveilla nce study was 20.4%.2 Ano ther con cern is macrolide resistance by Spn eumoniae, whic h in the United States and seve ral European countr ies is now more common than penicillin resistance.' In recent yea rs, the pre valence of S pn eumoniae isol ates resistant to multi ple classes of antimicrobial s has also increased.'
Th ese circums tanc es pose a cons iderable th erap eutic ch allen ge in e mpi ric prescribing. Am oxicillin/clavulanate has been availabl e in the clinic for more th an 20 years. Amoxicillin is a broad-spectrum antimic robia l, and c1avul an ate is a~-Iact ama s e inhibitor. The combinatio n covers most res piratory path ogen s, including S pneumonia e and the~-Ia ct am a s e-producin g organism s Haeinophilus infiuenzae and Mo raxe lla catarrhalis.
How e ver, in the United States, a mox ici lli n-pe nic illin cro ss-r esistan ce has been rep orted in mor e than 20 % of PRSP iso lates. ' Consequently, a formulation ca pable of eradica ting stra ins with reduced amoxic illin susceptibi lity is needed.
A new ph arm aco kin etically e nha nce d formulation of amox icillin/c1avulanate (2,000/125 mg) has been developed to era dica te strains of PRSP with amoxicilli n MICs as high as 4 ug/ml , This agent is give n as two 1,000/62. 5-mg Eraser" rubs the old data out of navigation. Clearing a new path in ENT surgery, Eraser keeps surgeons on top of anatomy changes with real-time updates to CT images.
Wiping away the need for extra intra-operative imaging, Erasing adds more. Circle 120 on Reader Service Card bilayer tabl ets twice a day. One layer of eac h tablet co ntains imm edi ate-release amoxici llin trihydr ate equi valent to 562.5 mg of am oxicillin , and potassium clavulan ate equivalent to 62. 5 mg of cla vulanic acid. Th e seco nd layer contains sustained-release crystall ine sodium amox icillin equiva lent to 437.5 mg of amox icillin. Thi s unique formulation ac hieves a mean serum time above MIC (T > MIC) of 49.4% of the 12-hour dos ing interval for an amox icillin MIC of 4 ug/rnl .' For amox ici llin/c lav ulanate, a serum T > MIC of 35 to 40 % of the dosing interval is predi cti ve of high bacteriolo gic efficacy. -? In an in vitro pharm acod ynami c model that sim ulated the hum an pha rmacokinetics of amoxi cillin/clavulanate 2,0001125 mg, significant redu ctions in bacterial count s were achi eved for S pneum on iae strains with amoxicillin MI Cs of 4 to 8 ug/rnl.? In in vivo animal models simulating hum an pharmacokin etics, the simulated dose equivalent to th is new fo rmulation of amox ici llin/c lav ulanate achieved high levels of bacteriologic success aga inst stra ins of S pneumoniae wit h amox icillin MIC s of 4 and 8 ug/rnl, as predicted by the T > MIC. 8 In this article, we present the res ults of a pooled efficacy ana lysis of amoxicillin/clav ulanate 2,0001125 mg in adult patient s with ABRS ca used by S pneunioniae, including PRSP, fro m two clinical trials.
Patients and methods
Data fro m two multinational (U.S. and cent ral and eas tern Euro pe), noncomparati ve studies of amoxici llin/clav ulanate 2,0001125 mg (given as two 1,000/62 .5 mg tabl ets twice daily ) in ad ult patient s with ABRS were evaluated in a pooled efficacy analysis . Selected data from one of these studies we re recently published. "
Both studies were co nducted in acco rda nce with Good Clinical Pract ice Guidelines and the Decl aration of Helsinki, as ame nde d in Som erset West, Republ ic of So uth Africa, in 1996. Study protocols for eac h trial were approved by national, local, or institutional ethics com mittees or review board s as appropria te for parti cipating ce nters . All patien ts provided wr itten and da ted informed co nse nt prior to study entry.
Study participants. Immunocompetent adults (age:~16 yr) with a diagnosis of ABRS of 3 to 28 days (for severe cases) or 7 to 28 day s (mild and moderate cases) were enrolled in the trials, provided they met the inclusion cr iter ia for the individ ual study in which they par ticipated.
A diag nosis of A BRS was based on a curre nt history of purulent nasa l discharge or purulenc e in the nasal cavity on exa mination and at least one major criter ion (fac ial pai n/press ure/tig htness over the affec ted sinus, facial co nges tion/fullness , or nasal obstruc tion/blockage) or at least two minor cri teria (nonvasc ular headache, co ugh , cha nge in percept ion of sme ll, sore throat, tooth pain , ea rac he, halitosis, per iorbital swe lling , and fever). Radiologicall y 502 co nfirmed (Waters ' view sinus x-ray or co mputed tom ograph y) rhinosinu siti s within 72 hours pri or to the study was also required. Fo r inclu sion in the study, patient s had to consent to initial sinus puncture.Arepeat sinus puncture was to be perform ed if clinical symptoms indicated a treatment failure or if sy mptoms rec urred. Patient s had to be suitable for oral therapy and willing and able to co mply with the study protocol. All wo men of child-bear ing potential had to have a negative urine pregnancy test before study entry. Th ese wo me n also had to agree to the use of adequate birth co ntro l measur es during the study per iod .
Patient s were exc luded from the stud ies if (I) they had a know n or suspected hypersensiti vity to study medications or related drugs, (2) they had a history of amox icillin/c lavulana te-associated cho lestatic jaundice or hepatic dysfunction, (3) they had previously experienced a reaction to study med ications or related dru gs, (4) they had rece ived antibacter ial therapy within 7 days before study entry, (5) they were participating in another clinical trial , or (6) they had received any investigational dru g or device within 30 days or within 5 half-lives of the inves tigatio nal dru g prior to the first dose of study medication . Patient s who had previously enro lled in any study ofamox icillin/cla vulanate 2,0001125 mg were ex cluded. Patients who had rece ived antibacterials as prophylaxis for any other indication within 7 days prior to enro llment were not exc luded, provided that this proph ylaxis was discont inu ed at study entry. Patients wit h a disease or medical co ndition that would co ntraindicate treatm ent with study med icat ions, incl uding known or suspec ted renal or liver impairme nt, we re also excl ude d, as were those who had a life-threatening or ser ious underl yin g disease likely to affect eva luation of study treatment efficacy. Other excl usion cr iteria were ( I) the presence of any disease or intraorb ital or intracranial complica tions that would interfere with diagnosis or eva luation of study medica tion efficacy, (2) a history of endoscopic sinus surge ry within 6 mon ths prior to st udy entry, (3) a history of chroni c rhinosi nusi tis, and (4) the presence of nasal polyp disease ex ten ding pro xim al to the middle turbinate. Also excluded were ( I) patient s who had taken prohibited co nco mitant medi cations (e.g., tubular sec retion inhibitors or corticos teroi ds> I0 mg/d ay predn iso ne orequiva lent), (2) patient s who we re active alcohol or drug abusers, and (3) patient s who req uire d hospit alization or pare ntera l antibacterial therapy. Pregn ancy, lactation, and inade quate birth contro l were reasons to disqualify female candidates.
Study population s. Th e safety population in both studies includ ed all patient s who had received at least one dose of study medi cation. Th e efficacy popul ation co nsisted of all patients in the safe ty popul ation who were clini cally eva luable and for whom efficacy result s co uld be verified. The bacteriology popul ation was a subse t of the efficacy popul ation and included all patie nts who had at least one
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Ci rcl e 12 1 on Reader Servic e C ard pathogen isolated at screening. Th e primary pop ulatio n of interest was the bacteriology population .
Bacteriologic assessm ent. Bacteriologic assessments were carried out at study entry and, when possi ble, at the end of therapy and the end of follow -up; in some patien ts, assessments were made at the tim e of treatment fai lure or upon recurrence of sy mptoms . Pathogens were isolated from sin us samples obtained via antra l punctu re.
Qua ntitative culture, iden tification, and susce ptibi lity testing were performed at cen tra l laboratories. M ICs were determi ned using broth microdiluti on for aero bic pathogens, according to National Committee for Clinical Laboratory Standards (NCCLS) guidelines.10 Isolates were classified as susceptible, intermedia te, or resistant based on NCC LS interpretative breakpoints.to NCCL S breakpoints do not yet exist fo r amoxici llin/clavulanate 2,000/12 5 mg; therefore, susceptibility to this agent was based on bre akpo ints for establis hed form ulations.
Effic acy assessm ents. Follow ing enro llme nt, patients were required to atten d the clinic three times: an on-thera py visit (day 2 to 10), an end-of-therapy visit (day II to 16) , and a foll ow-up visit (day 17 to 28) .
For the purp oses ofthis pooled efficacy analysis, success for patie nts in the bacteriology population was define d as eradica tion of the infecting pathogen or, in the absence of an evaluable repeat sinus culture, clinical evidence of eradication (sufficient improvement in the signs and symptoms of ABRS recor ded at screening such that no additional antibacteria l therapy was indicated). Failure was defined as persistence of the initial pathoge n (i.e., the pathogen was persistent in an eva luable repeat sinus culture) or pres umed persistence ofthe infecting pathogen at the end-of-therapy visit (i.e., an eva luable repeat sinus culture was abse nt and the patie nt had clinical signs or symptoms of ABRS necessitating further antimicrobial thera py) .At the primary endpoi nt (fo llow -up visit), failure was defined as ( I) rec urrence in an eval uab le sinus culture of the initial pathogen that was era dica ted or presumed era dica ted at the end-oftherapy visit or (2) clinical evidence of recurre nce of the initial pathogen in the absence of a repeat sin us culture. A failure recorded at the end -of-therapy visi t was car ried forward to the follow-up visit. The patient's bacterio logic response was base d on the bacteriologic outcome for eac h pathogen identified at screen ing .
For each study populatio n, 95 % confidence intervals (CIs) were calc ulated for the success rates using exact methodology.
Safety assessm ent. Adverse even ts were recorded at the on-therapy visit and for as long as 30 days post -thera py. Adve rse events were defined as any untoward medical occurrence in patients rece iving study medication, but they did not necessari ly have to be related to study medication. Anticipated day-to-day fluctuations in preexisting conditions-including the condition under investigation, 50 4 signs and symptoms, or expected progression of the disease under inves tigation-were not cons idered adverse even ts unless they represented a significant worsening of the condition. All adverse events were reco rded using the Medical Dictionary for Regulatory Activities Terminology (MedDRA) by body system and preferred term .
A serio us adverse even t was any eve nt that was fata l, life-threaten ing, or permanently or temp orarily incapacitating or disabling, or that res ulted in hospitalization. Elective surgery and routine clinical procedures requiri ng hospitalization were not disq ualifyi ng, provided that they were comp leted witho ut complication and not carrie d out as the result of an adverse eve nt. Any eve nt that pro longed a hospita l stay or was associated with congenital abnormality, cancer, overdose (acci den tal or intentional), or pregnancy was also considered a serious adverse eve nt. Additiona lly, any even t that the inves tigator considered to be ser ious or that suggested any sign ificant hazard, contrai ndicatio n, side effec t, or preca utio n possi bly related to study medication was recorded as serio us.
Th e severity of eac h adverse eve nt and its relationship to study medication were assessed by the investigator. Patients who withdrew early from the study or who were co nsidered clin ical failures underwent a safe ty assess ment when they left the study.
Results
Patient disposition and demograph ics. A total of 2,482
patients were included in the safe ty pop ulation. Of these, 2,32 4 were inclu ded in the efficacy pop ulatio n. In both studies, mos t patients were female and white (table).
Baseline bacteriology. A total of 1,379 pathogens were isolated fro m 1,156 patients at screening (bac teriology population). The mos t frequentl y isolated pathogen was S pneumoniae, which was isolate d fro m 37 1 patients in the bacterio logy populatio n. Amo ng this pop ulation, 37 patients ( 10.0%) had a total of 37 isolates of PRSP.A total of 73 (19 .7%) S pneu mon iae isolates in the bacteriology populatio n at screening were resistant to eryt hromyci n (ery thro myci n MICs: ;:::; 1 ug/rnl ).
Of the S pneumoniae isolates, 5 (1. did not und ergo repeat sinus puncture at follow-up , and therefore bacterial infection was pres umed to be persistent or recurrent based on clinical assessment. One patient was considered a clinical failure even though eradica tion of S pneum oniae was confirmed. Two other patients were classified as failures based on radio logic result s, and another on the basis of radiologic results, cli nical symptoms, and a presumed recurrence ofS pneumoniae infection. S pneumo niae was eradica ted in 2 other patients who were classified as treatm ent failures, but I patient then experie nced a recurrence of Escherichia coli infect ion and the other experienced a recurr ence of clinical symptoms and a new infection with M catarrhalis. None of the S pneumoniae isolated from these patient s was penicillin-resistant, with the exce ptio n of the I patient who was classified a treatment failure on the basis of radio log ic results. Safety. Dur ing the on-therapy period and within 30 days post-therapy, 933 of the 2,482 patie nts (37.6 %) in the safety populatio n experienced at least one adverse event. The most co mmo n was diarrhea, whic h was repor ted by 409 patients (16 .5%); most of these cases were mild to moderate in intensity. The only other adverse even ts to occ ur in more than 2% of patient s were 74 cases of genital moniliasis (3.0%) and 59 cases of nausea (2.4 %).
The withdrawal rate was low, as only 54 patients (2.2 %) dropped out because of any adve rse eve nt. Nine patient s (0.4 %) experienced at least one serio us adve rse event.
No deaths occ urred during the on-therapy period or within 30 days after the cessa tion of therapy.
Discussion
A pooled efficacy analysis provides a means to evaluate the efficacy of a drug against larger numbers of resistant pathoge ns than could be found in any indivi dual clinical trial. In the two studies included in this analysis, 37 cases of PRSP( 10.0% of allSpne utnon iae cases) were identified. Eight patients with PRSP (2 1.6% ofPRSP patients and 2.2% of all S pneumoniae patients) had amox icillin/clav ulanic acid MICs of4/2 ug/rnl or higher. Although the perce ntage of PRSP isolates in this study was lower than what was fou nd in the United States in the Alexa nder Project surveillance (25%), it was slightly higherthan the prevalence that was found in Eastern Europe (7.8 %) .2The relative ly low percentage of PRSP recove red in the poo led studies may reflect the design of the individu al trials included in the analysis . For example, recent antimi crobial use and immunodeficiency are both risk fac tors for infection with PRSP,I and such patients would have been exc luded from the individual clinical trials.Also, some study centers might have been located in areas of lower resis tance than the centers includ ed in the Alexa nder Project, and this might have contributed to this difference.
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Fast Tract is a surgical procedure that places our SCOop® oxygen catheter in the patient's trachea. success in patie nts with ABRS ca used by S pneunioniae (93 .0% of the bac ter iology popul ation), includi ng 97 .3% of patient s with PRSP infection and 87.5% of patients with elevated amoxici llin!clav ulanic acid MI Cs. Th ese high rates of success are consistent with results obtained with amoxicillin/clav ulanate 2,00 01125 mg in in vitro pharmacokin etic studies and in vivo ani ma l studies that simulated the human pharmacokineti cs of amoxicillinl clav ulanate 2,0001125 mg .7.8 In both in vitro and in vivo studies, amox icillin/clavulanate 2,0001125 mg demonstrated high bactericidal activi ty agai nst S pn eunion iae, includ ing strains with amox icillin/clavulanic ac id M ICs of 4/2 and 8/4 ug/rnl ; " Bacterial eradication is believed to playa key role in ma ximizing cli nical outcomes in respiratory tract infections, and it may help redu ce the spread of antimicrobialres istant organisms. I I It is important that the antimicrobials selec ted for empiric therapy of ABRS have bee n documented as efficacious agai nst the likely infecting orga nisms.'? As the res ults of our analysis dem onstrate, amox icillin /clav ulanate 2,0001125 mg is highl y effe ctive agai nst S pn eumoniae, the most co mmo n patho gen isolated in patients with ABRS. The co mbination of amoxicilli n and the~-l a ct am a s e inhibitor clav ulanate also makes it a suitab le antimicro bial for infectio ns caused by H influen zae and by M catarrhalis.
In additio n to efficacy, safety and tolera bility need to be taken into account when prescribing. Amoxici llinl clavulanate has been clini cally ava ilable for more tha n 20 years and has an esta blished safe ty profile.l-!' Th e safety profile of the 2,0 0011 25-mg formu latio n has been shown to be similar to that of co nve ntio nal form ulations. v-" In the two studies inclu ded in our analys is, the co mbination was we ll tolerated, and few patients withdrew fro m studies becau se of adverse eve nts.
Thi s new form ulation of amox icillin/clavulanate provides a valua ble treatment option for the empiric therapy of ABRS, par ticularly in areas where antimicrobial-resistant (including~-l a c t a m a s e-po s i t i v e ) pathogens are prevalent, and in patients who are at increased risk of infection with PRSP.
